{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:12:32Z","timestamp":1787508752640,"version":"build-2736575974"},"reference-count":17,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medical Case Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>The proteasome inhibitor bortezomib is widely used in the treatment of multiple myeloma. While peripheral neuropathy and gastrointestinal effects are well-documented adverse reactions to bortezomib administration, cutaneous side effects in patients with multiple myeloma are less commonly reported. We present a patient with IgG kappa multiple myeloma who developed a spider-like and digitate eruption at the site of subcutaneous bortezomib injection. This report expands the spectrum of bortezomib-associated dermatologic toxicity and emphasizes the importance of clinician awareness for prompt diagnosis and management.<\/jats:p>","DOI":"10.1177\/2050313x251411508","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:20:11Z","timestamp":1768396811000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of a digitate injection site reaction from subcutaneous bortezomib in a patient with myeloma"],"prefix":"10.1177","volume":"14","author":[{"given":"Rachel","family":"Creighton","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamryn","family":"Eglington","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke Y. C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology, Dalhousie University, Halifax, NS, Canada"},{"name":"Division of Hematology, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0734-1769","authenticated-orcid":false,"given":"Ashley E.","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"issue":"9","key":"e_1_3_2_3_2","first-page":"1221","article-title":"Global, regional, and national burden of multiple myeloma, 1990\u20132016: results from the Global Burden of Disease Study 2016","volume":"4","author":"GBD 2016 Multiple Myeloma Collaborators","year":"2018","unstructured":"GBD 2016 Multiple Myeloma Collaborators. Global, regional, and national burden of multiple myeloma, 1990\u20132016: results from the Global Burden of Disease Study 2016. JAMA Oncol 2018; 4(9): 1221\u20131227.","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1361"},{"key":"e_1_3_2_7_2","first-page":"21","article-title":"Management of patients with multiple myeloma treated with bortezomib: recommendations of an expert panel","volume":"6","author":"O\u2019Connor OA","year":"2008","unstructured":"O\u2019Connor OA, Stewart AK, Vallone M, et al. Management of patients with multiple myeloma treated with bortezomib: recommendations of an expert panel. J Support Oncol 2008; 6(6 suppl 2): 21\u201332.","journal-title":"J Support Oncol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07757.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.030"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1404a243"},{"key":"e_1_3_2_12_2","first-page":"441","article-title":"Skin rash as a side effect of bortezomib: a case report","volume":"17","author":"Elboraey AM","year":"2023","unstructured":"Elboraey AM, Abouelnour SM, Saleh HS, et al. Skin rash as a side effect of bortezomib: a case report. J Med Case Rep 2023; 17: 441.","journal-title":"J Med Case Rep"},{"issue":"6","key":"e_1_3_2_13_2","first-page":"406","article-title":"Subcutaneous administration of bortezomib: strategies to reduce injection site reactions","volume":"3","author":"Kurtin S","year":"2012","unstructured":"Kurtin S, Knop CS, Milliron T. Subcutaneous administration of bortezomib: strategies to reduce injection site reactions. J Adv Pract Oncol 2012; 3(6): 406\u2013410.","journal-title":"J Adv Pract Oncol"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16049"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/dermatopathology10030031"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1167-x"},{"key":"e_1_3_2_17_2","unstructured":"Pfizer Medical Information. Bortezomib: adverse reactions \u2013 discontinuation due to toxicity https:\/\/www.pfizermedicalinformation.com\/bortezomib\/adverse-reactions (2022 accessed 6 May 2025)."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/JNN.0b013e3181ee122b"}],"container-title":["Sage Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X251411508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X251411508","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X251411508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T20:36:28Z","timestamp":1769373388000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X251411508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"alternative-id":["10.1177\/2050313X251411508"],"URL":"https:\/\/doi.org\/10.1177\/2050313x251411508","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"2050313X251411508"}}